Literature DB >> 9521134

Decline of measles-specific immunoglobulin M antibodies after primary measles, mumps, and rubella vaccination.

R F Helfand1, H E Gary, W L Atkinson, J D Nordin, H L Keyserling, W J Bellini.   

Abstract

Detection of measles-specific immunoglobulin M (IgM) has become the standard diagnostic method for laboratory confirmation of measles. In outbreaks, the interpretation of an IgM-positive result can be complicated when persons with suspected measles receive a dose of measles vaccine as part of outbreak control measures. This investigation evaluated the decay of measles-specific IgM antibodies 1 to 4 months after primary vaccination with measles, mumps, and rubella vaccine (MMRII). Serum samples were obtained from 536 infants vaccinated when they were 15 months old as part of a study to assess primary and secondary measles vaccine failure. Sixty serum specimens per week were selected from specimens collected between 4 and 9 weeks after MMRII vaccination; all 176 available serum specimens collected between 10 and > or = 16 weeks were included. Specimens were tested for the presence of measles-specific IgM by an antibody-capture enzyme immunoassay. The proportion of IgM-positive specimens dropped from 73% at 4 weeks after vaccination to 52% at 5 weeks after vaccination and then declined to 7% by 8 weeks after vaccination. Less than 10% of children remained IgM positive between 9 and 11 weeks. An IgM-negative result helps rule out the diagnosis of measles in a person with suspected infection and a history of recent vaccination. The interpretation of a positive IgM result from a person with a clinically suspected case of measles and a recent history of measles vaccination (especially within 8 weeks) is problematic, and the diagnosis of measles should be based on epidemiologic linkage to a confirmed case or on detection of wild-type measles virus.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9521134      PMCID: PMC121349          DOI: 10.1128/CDLI.5.2.135-138.1998

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  4 in total

1.  Diagnosis of measles with an IgM capture EIA: the optimal timing of specimen collection after rash onset.

Authors:  R F Helfand; J L Heath; L J Anderson; E F Maes; D Guris; W J Bellini
Journal:  J Infect Dis       Date:  1997-01       Impact factor: 5.226

2.  Case definitions for infectious conditions under public health surveillance. Centers for Disease Control and Prevention.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1997-05-02

3.  Evaluation of monoclonal antibody-based capture enzyme immunoassays for detection of specific antibodies to measles virus.

Authors:  D D Erdman; L J Anderson; D R Adams; J A Stewart; L E Markowitz; W J Bellini
Journal:  J Clin Microbiol       Date:  1991-07       Impact factor: 5.948

4.  Baculovirus expression of the nucleoprotein gene of measles virus and utility of the recombinant protein in diagnostic enzyme immunoassays.

Authors:  K B Hummel; D D Erdman; J Heath; W J Bellini
Journal:  J Clin Microbiol       Date:  1992-11       Impact factor: 5.948

  4 in total
  4 in total

1.  IgM production by bone marrow plasmablasts contributes to long-term protection against intracellular bacterial infection.

Authors:  Rachael Racine; Maura McLaughlin; Derek D Jones; Susan T Wittmer; Katherine C MacNamara; David L Woodland; Gary M Winslow
Journal:  J Immunol       Date:  2010-12-08       Impact factor: 5.422

2.  Timing of development of measles-specific immunoglobulin M and G after primary measles vaccination.

Authors:  R F Helfand; S Kebede; H E Gary; H Beyene; W J Bellini
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

3.  Lack of evidence of endogenous avian leukosis virus and endogenous avian retrovirus transmission to measles, mumps, and rubella vaccine recipients.

Authors:  A I Hussain; V Shanmugam; W M Switzer; S X Tsang; A Fadly; D Thea; R Helfand; W J Bellini; T M Folks; W Heneine
Journal:  Emerg Infect Dis       Date:  2001 Jan-Feb       Impact factor: 6.883

4.  The optimal vaccination strategy to control COVID-19: a modeling study in Wuhan City, China.

Authors:  Ze-Yu Zhao; Yan Niu; Li Luo; Qing-Qing Hu; Tian-Long Yang; Mei-Jie Chu; Qiu-Ping Chen; Zhao Lei; Jia Rui; Cheng-Long Song; Sheng-Nan Lin; Yao Wang; Jing-Wen Xu; Yuan-Zhao Zhu; Xing-Chun Liu; Meng Yang; Jie-Feng Huang; Wei-Kang Liu; Bin Deng; Chan Liu; Zhuo-Yang Li; Pei-Hua Li; Yan-Hua Su; Ben-Hua Zhao; Wen-Long Huang; Roger Frutos; Tian-Mu Chen
Journal:  Infect Dis Poverty       Date:  2021-12-28       Impact factor: 4.520

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.